SWOG clinical trial number
S2114

A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma

Open
Phase
Accrual
62%
Abbreviated Title
Ph II consolidation therapy following CD19 CAR-T for R/R DLBCL or Gr III FL
Status Notes
Activated: Effective Thursday, February 23, 2023 at 12:00 PM Pacific Time
Activated
02/23/2023
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS

Research committees

Lymphoma

Treatment

Mosunetuzumab Polatuzumab vedotin

Patient Study Materials

Patient Clinical Trial Summary
Download PDF of Patient Clinical Trial Summary

Other Study Materials

Eligibility Criteria Expand/Collapse

*Please review Section 5: Eligibility of the protocol for eligibility criteria.*

Publication Information Expand/Collapse

2023

SWOG 2114: A Randomized Phase II Trial of Consolidation Therapy following CD19 CAR T-cell Treatment for Relapsed/Refractory Large B-cell or Grade IIIB Follicular Lymphoma

B Hess;H Li;N Hossain;V Beylergil;C Sauter;M Hamadani;J Svoboda;A Major;B Kahl;J Leonard;S Smith;M LeBlanc;P Stiff;JW Friedberg Hematology Oncology Vol 41, Issue S2; ICML (June 13 to June 17, 2023, Lugano, Switzerland), publication only

2022

A non-factorial analysis of a factorial Phase II trial design to evaluate single agent and combination consolidation therapies following CD19 CAR T-cell therapy for relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL): SWOG-S2114

H Li;M LeBlanc;B Hess;N Hossain;SM Smith;P Stiff;J Friedberg Society for Clinical Trials (MAY 15-18, 2022 San Diego, CA), poster

Reports & Approvals

Trial Locations

Other Clinical Trials

SWOG Clinical Trial Number
S2506

MOZART MZL: A Randomized Phase II Study with a Common Control Arm of Mosunetuzumab Monotherapy Evaluated Against Two Experimental Treatment Arms of Either Combination Mosunetuzumab and Zanubrutinib or Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients with Relapsed/Refractory Marginal Zone Lymphoma
Research Committee(s)
Lymphoma
Activated
08/18/2026
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA4232

A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Research Committee(s)
Lymphoma
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2308

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
69%
Open
Phase